Ricevi le ultime notizie sulle azioni Repare Therapeutics con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di RPTX

Ultime notizie per

REPARE THERAPEUTICS INC

Repare Therapeutics

Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.

Cathie Wood Defies CoreWeave IPO Slump, Ark Snaps Up $3.6 Million Worth Of Stock In Nvidia-Backed Company

Equities

News

Markets

ETFs

ARKK

GTLB

HOOD

PATH

RPTX

Investimenti mirati: la società di investimento continua a puntare sulla piattaforma finanziaria nonostante le incertezze del mercato.

Cathie Wood raddoppia acquistando milioni di azioni nonostante i dazi di Trump

Trump’s Economic Gambit Sparks Fierce Debate As Cathie Wood Sees A Reagan-Style Boom, Obama Adviser Calls Musk’s Role A ‘Performance Art’

ARKG

ARKW

DKNG

EXAS

L&#39;investimento massiccio punta su due società innovative nel settore sanitario e dello sviluppo software. Cosa bolle in pentola?

Ark Invest di Cathie Wood scommette sull&#39;IA: ecco chi ha comprato

Repare Therapeutics Inc

Press Releases

Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions

Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Repare Therapeutics Announces Leadership Transitions

Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025

Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics

Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates

Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib

OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee

Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

IMNM

INSM

KURA

ABVC BioPharma

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

Alterity Therapeutics Limited - American Depositary Shares

Alterity Therapeutics

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

BeyondSpring

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

Cibus

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

CervoMed

Cue Biopharma

Fortress Biotech

Gain Therapeutics

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

Immix Biopharma

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics

Lite Strategy

OKYO Pharma

PMV Pharma

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Plus Therapeutics

Pelthos Therapeutics

Sutro Biopharma

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics

XBiotech

X4 Pharmaceuticals

HC Wainwright & Co.

Stifel

Piper Sandler

Morgan Stanley

Comments

Repare Therapeutics Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO